Participant flow

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · Source last updated 2024-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   * Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

   id

   FG000

   title

   Ovarian Cancer (OvC)

2. description

   * Metastatic CRC previously treated with ≥ 2 lines of prior systematic chemotherapies * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

   id

   FG001

   title

   Colorectal Cancer (CRC)

3. description

   * Advanced SCLC previously treated with one line of prior systemic chemotherapy * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

   id

   FG002

   title

   Small Cell Lung Cancer (SCLC)

4. description

   * TNBC previously treated with one line of prior systemic chemotherapy * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

   id

   FG003

   title

   Triple Negative Breast Cancer (TNBC)

5. description

   * AML (any age) who are not eligible for allogeneic hematopoietic stem cell transplant and have been able to achieve partial response (PR) while receiving frontline therapy with hypomethylating agents (HMAs) * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

   id

   FG004

   title

   Acute Myelogenous Leukemia (AML)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         25

      2. comment

         This arm only enrolled 1 subject before it was closed. Subject was not included in the efficacy or safety analyses.

         group Id

         FG001

         num Subjects

         1

      3. comment

         This arm was not opened

         group Id

         FG002

         num Subjects

         0

      4. comment

         This arm was not opened

         group Id

         FG003

         num Subjects

         0

      5. comment

         This arm was not opened

         group Id

         FG004

         num Subjects

         0

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      2. comment

         This arm only enrolled 1 subject before it was closed. Subject was not included in the efficacy or safety analyses.

         group Id

         FG001

         num Subjects

         1

      3. comment

         This arm was not opened

         group Id

         FG002

         num Subjects

         0

      4. comment

         This arm was not opened

         group Id

         FG003

         num Subjects

         0

      5. comment

         This arm was not opened

         group Id

         FG004

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice